



Company Overview

Aethlon Medical develops immunotherapeutic technologies to combat cancer and infectious disease. The Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a "Breakthrough Device" for 1) the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and 2) life-threatening viruses that are not addressed with approved therapies.

Aethlon Medical is currently conducting a clinical trial in Sars-CoV-2 in India and are in the process of launching an oncology clinical trial in Australia.

Aethlon Medical Enters Into Materials Transfer Agreement for Santerus AG's NucleoCapture and HemoNucleoCapture Devices

Feb 21 2024, 8:01 AM EST

Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update

Feb 14 2024, 4:15 PM EST

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024

Feb 7 2024, 8:00 AM EST

Stock Overview

Symbol	AEMD
Exchange	Nasdaq
Market Cap	3.71m
Last Price	\$1.41
52-Week Range	\$1.35 - \$7.20

04/18/2024 03:58 PM EDT

Executive Team

James B. Frakes

Interim Chief Executive Officer and Chief Financial Officer

Guy Cipriani

Chief Operating Officer

Lee D. Arnold, PhD

Chief Scientific Officer

Steven LaRosa, M.D.

Chief Medical Officer

John Nguyen

Vice President of Manufacturing

Aethlon Medical, Inc.

11555 Sorrento Valley Road
Suite 203
San Diego, CA 92121

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.